Marta Arias-Salgado was appointed Vice President and Global Head of Global Clinical Trial Operations (GCTO) Regions and Regional Operations (RRO) in April 2025. She manages the GCTO RRO leadership team in managing clinical operations, including trial execution and support functions.

Marta began her career at Merck in 1998 and has held various leadership roles, focusing on quality improvement, regulatory inspections, and clinical supply chain management.

Marta received a Bachelor of Science degree in biochemistry and molecular biology from UAM University in Madrid, Spain. She also holds a Master of Science degree in Research & Development from Navarra University.

Dr Kenneth Waterman received his B.S. degree with honors in Chemistry from UCLA, his Ph.D. in Physical Organic Chemistry from UC Berkeley and conducted post-doctoral studies in physical and photo-chemistry as an NIH Research Fellow at Columbia University. Dr Waterman’s distinguished career includes 12 years as a scientist at Polaroid working to develop imaging products, and 13 years as a Research Fellow at Pfizer working on drug stability, drug delivery, biopharmaceutics and prodrugs, before founding FreeThink Technologies, a laboratory and software company with unique expertise in stability, packaging and formulations. In addition, FreeThink produces and licenses its advanced accelerated stability software, ASAPprime®. He is an AAPS Fellow and the author of over 75 publications/patents.

Mario Torchia gained 15 years of experience in the tech industry, working in multinational companies such as Dassault Systèmes and Siemens. Most recently he led the Sales Strategy as Delmia Geo Leader for South Europe at Dassault Systèmes, actively supporting customers in their business transformation journey.  Previously, he spent four years in Sao Paulo, managing the Brazilian branch of Hyla Soft, a global IT company that provides technology solutions to improve productivity and efficiency within Manufacturing Engineering, Manufacturing Operations and Sales and Operations Planning processes.  Holding a degree in Computer Engineering, Torchia is passionate about technology, innovation, arts, and water sports. He is currently the Chief Operating Officer (COO) at InSilicoTrials, having previously led the sales and marketing team. Torchia leverages his extensive experience with large and medium-sized companies, strategic market vision, and skills in helping startups expand in international markets.

Matt Holms is the VP of Sales responsible for overseeing Patient Engagement & Recruitment Solutions at Citeline. He has spent 24 years in the Life Science industry, holding various commercial & executive leadership roles, dedicated to driving innovative technology solutions that enhance clinical research across a diverse spectrum of eClinical technology, Patient Recruitment/RWD, and Sponsor organizations. Beyond his professional endeavors, he is passionate about patient access and awareness of clinical research opportunities, having personally experienced life-changing results and benefits as a clinical research study participant.

Dr. Abhijeet Maurya is a pharmaceutical scientist with a diverse background in product development and process optimization. Currently serving as a Process Development Principal Scientist at Amgen, he is an integral part of the synthetics prepivotal team, focusing on enabling technologies to overcome challenges associated with the dosing properties of complex drug molecules. Dr. Maurya has held key positions at Adare Pharma Solutions and Bend Research and began his career as an ORISE Post-doctoral fellow at the U.S. FDA's Office of Pharmaceutical Quality. He is a member of the Editorial Advisory Board of AAPS PharmSciTech and has published numerous articles and book chapters.

Mrs. Spaziani has over 25 years of experience within the clinical research industry on both the sponsor and CRO side. Starting as a Clinical Research Associate, Mrs. Spaziani was rapidly promoted to regional and global clinical management positions. Mrs. Spaziani has extensive and diverse experience with study feasibility and study start-up through study closure and archival including protocol and CRF development, site selection, Investigator Meeting management, clinical study site monitoring, vendor management, and collaborating on clinical study reports and IND Updates. Mrs. Spaziani has supported global clinical study management by utilizing data to accurately forecast recruitment projections, select quality enrolling sites, and meet planned recruitment commitments. She has spent the last 15 years focused on study start-up.

Dr LeBel is the founder of CPL Bioconsulting, LLC., a consulting firm that assists biotech clients with their corporate and drug development strategies. He also serves as Chief Executive Officer for pacDNA, Inc., a Northeastern University spinout focused on improving the potential of oligonucleotide therapeutics. From 2018-2023 Dr LeBel served as Chief Development Officer for Frequency Therapeutics, Inc., a development stage biotech company focused on treatments for sensorineural hearing loss. Before that he was Entrepreneur-in-Residence and Affiliate Associate Professor in the Bouvé College of Health Sciences at Northeastern University, where he assisted faculty, students, and alumni with forming and guiding their startups. Prior to that Dr LeBel was the Chief Scientific Officer at Otonomy, Inc., from 2009-2017 where he was responsible for all R&D activities focused on discovery and development of biotherapeutics to treat conditions of the ear. Before that he was President and CEO at Akesis Pharmaceuticals, Inc., a public metabolic disease firm. Additionally, he held numerous R&D management positions during a 14-year tenure at Amgen Inc. Prior to that he held pharmacology/toxicology positions at Alkermes, Inc. and Arthur D. Little, Inc. Dr LeBel obtained a BS in Chemistry from the University of Detroit, a PhD in Biomedical Sciences/Toxicology from Northeastern University, and he was a NIEHS postdoctoral fellow in Community and Environmental Medicine at the University of California, Irvine.

Dr Colin McKinlay is the senior director of chemistry and delivery technologies at Nutcracker Therapeutics. He has significant expertise in nucleic acid delivery through his doctoral research at Stanford University with professors Paul Wender and Robert Waymouth. Dr McKinlay’s research involved preparation of synthetic delivery vehicles through organocatalytic ring-opening polymerization; their characterization; and in vitro and in vivo evaluation for the delivery of DNA, RNA, and other biological macromolecules. He holds over five patents and has nine peer-reviewed publications on chemical delivery technologies. Dr McKinlay has led the delivery efforts at Nutcracker Therapeutics since 2018, including the establishment of its unique peptoid-based Nutshell® delivery platform.

Currently, as the Head of Patient & Site Engagement Capabilities, Tracey leads a team that is responsible for the development the global solutions and processes supporting all aspects patient and site engagement including the use of decentralized technologies in trials. She started her career in consulting working for Coopers & Lybrand / PricewaterhouseCoopers on projects across a broad cross-section of pharmaceutical clients. Prior to her current role at Boehringer she has worked across Medicine leading the business activities for global systems implementations, in IT heading support for Regulatory Submissions Management, and in Biostatistics & Data Science as the Digital Trials team lead. Her career to date has taken her from the UK to US, Germany and back to the US. Typically, she is responsible for strategy development, leadership, project management, process harmonization, innovation, and organizational change management. She has a Bachelor of Science (Hons) in Technology & Business Studies (Production Engineering and Economics) from Strathclyde University, and an MBA Information Management from Robert Gordon University (Scotland, UK). She is Project Management Professional (PMP) and Certified Scrum Master (CSM). 

Mr Dundon leads Drug Delivery Systems Strategy at Jabil Pharma Delivery Solutions. Jabil Pharma Delivery Solutions is the largest supplier of drug delivery systems to our Pharma partners. Mr Dundon has responsibility for monitoring our pharma partners clinical pipelines and business strategies to understand our pharma partners drug delivery opportunities/challenges to identify potential drug delivery systems technologies and/or services that Jabil can offer to realise our pharma partners business objectives.

Prior to working with Jabil, Mr Dundon had a 30-year career at GSK where he assumed various position of increasing responsibility culminating in leading the Device Engineering R&D Group. He was responsible for the design, development, registration & industrialisation of a series of drug delivery systems across a range of routes of administration. He created a process for the implementation of Quality by Design for drug delivery devices utilising mechanistic modelling and in-silico simulation tools, that has been endorsed by an external industry consortia. In addition, Mr Dundon was responsible for the proposal and implementation of a Change Management Process for Drug Delivery Systems that has been developed as an ISO Standard.

Mrs. Bhagwat has a Masters degree in Pharmaceutical Sciences along with several years of work experience in the pharmaceutical industry around generic product development and filing. With a degree in intellectual property, she also worked on developing IP strategies in her previous role. After an MBA degree in International Management and consulting experience in the pharmaceutical industry, she now works at Merck KGaA, Darmstadt, Germany as a Strategic Product manager. Her primary responsibility lies in the field of excipients used for solid formulation drug development. She is leading the digital strategy for solid formulation with its flagship product mPredict™.

Chung-Hsin Wang holds a Ph.D. in Biomedical Engineering from Tsing Hua University and has over 15 years of experience researching lipid-based ultrasound contrast agents and ultrasound imaging and drug delivery technologies. Dr Wang is the founder of Trust Bio-sonics, which currently has several new drug candidates, including a next-generation diagnostic ultrasound contrast agent (in Phase III clinical trials), targeted/molecular ultrasound contrast agents, and an ultrasound drug delivery platform designed to enhance conventional chemotherapy and immunotherapy for wide-range oncology applications.

Trust Bio-sonics aims to provide comprehensive medical solutions from early diagnosis to treatment throughout the patient care cycle, helping patients access treatment more quickly and return to a fulfilling life.